The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes

Brain Research Bulletin

Volumn 48, Issue 6, 1999, Pages 641-647

  Wells, Gregg B ^a   Lopez, Melissa C ^b   Tanaka, Jacqueline C ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Dopamine release; Dopamine transporter; Dopamine uptake; Ibogaine; Serotonin transporter; Serotonin uptake; Synaptosomes

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; IBOGAINE; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BRAIN SYNAPTOSOME; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG EFFECT; DRUG PROTEIN BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONIN UPTAKE;

EID: 0033064869     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(99)00053-2     Document Type: Article

References (50)

1. Ali S.F., Newport G.D., Slikker W., Rothman R.B., Baumann M.H. Neuroendocrine and neurochemical effects of acute ibogaine administration: A time course evaluation. Brain Res. 737:1996;215-220.
2. Annunziato L., Leblanc P., Kordon C., Weiner R.I. Differences in the kinetics of dopamine uptake in synaptosome preparations of the median eminence relative to other dopaminergically innervated brain regions. Neuroendocrinology. 31:1980;316-320.
3. Badio B., Padgett W.L., Daly J.W. Ibogaine: A potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol. Pharmacol. 51:1997;1-5.
4. Baumann M.H., Char G.U., DeCosta B.R., Rice K.C., Rothman R.B. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J. Pharmacol. Exp. Ther. 271:1994;1216-1222.
5. Bhargava H.N., Cao Y.J., Zhao G.M. Effects of ibogaine and noribogaine on the antinociceptive action of μ, δ, and κ opioid receptor agonists in mice. Brain Res. 752:1997;234-238.
6. 2 receptor-selective ligands with moderate affinity. Eur. J. Pharmacol. 279:1995;R1-R3.
7. Broderick P.A., Phelan F.T., Eng F., Wechsler R.T. Ibogaine modulates cocaine responses which are altered due to environmental habituation: In vivo microvoltammetric and behavioral studies. Pharmacol. Biochem. Behav. 49:1994;711-728.
8. Cappendijk S.L.T., Dzoljic M.R. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur. J. Pharmacol. 241:1993;261-265.
9. 3H] 5-hydroxytryptamine into rat cortical synaptosomes. Eur. J. Pharmacol. 239:1993;211-214.
10. Deecher D.C., Teitler M., Soderlund D.M., Bornmann W.G., Kuehne M.E., Glick S.D. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 571:1992;242-247.
11. Elsworth J.D., Taylor J.R., Berger P., Roth R.H. Cocaine-sensitive and -insensitive dopamine uptake in prefrontal cortex, nucleus accumbens and striatum. Neurochem. Int. 23:1993;61-69.
12. Gawin F.H. Cocaine addiction: Psychology and neurophysiology. Science. 251:1991;1580-1586.
13. Glick S.D., Kuehne M.E., Maisonneuve I.J., Bandarage U.K., Molinari H.H. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: Effects of morphine and cocaine self-administration and mesolimbic dopamine release in rats. Brain Res. 719:1996;29-35.
14. Glick S.D., Maisonneuve I.M. Mechanism of antiaddictive actions of ibogaine. Ann. N. Y. Acad. Sci. 844:1998;214-226.
15. Glick S.D., Maisonneuve I.M., Visker K.E., Fritz K.A., Bandarage U.K., Kuehne M.E. 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology. 139:1998;274-280.
16. Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., Carlson J.N. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:1991;341-345.
17. Glick S.D., Rossman K., Wang S., Dong N., Keller R.W. Jr. Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: Interactions with D-amphetamine. Brain Res. 628:1993;201-208.
18. Gray E.G., Whittaker V.P. The isolation of nerve endings from brain: An electron microscopic study of cell fragments derived by homogenization and centrifugation. J. Anat. 96:1962;79-87.
19. Green A.I., Snyder S.H., Iversen L.L. Separation of catecholamine-storing synaptosomes in different regions of rat brain. J. Pharmacol. Exp. Ther. 168:1969;264-271.
20. Harsing L.G. Jr, Sershen H., Lajtha A. Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum. J. Neural Transm. 96:1994;215-225.
21. Itzhak Y., Ali S.F. Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain. Ann. N. Y. Acad. Sci. 844:1998;245-251.
22. Kuehne M.E., Reider P.J. A synthesis of ibogamine. J. Org. Chem. 50:1985;1464-1467.
23. Layer R.T., Skolnick P., Bertha C.M., Bandarage U.K., Kuehne M.E., Popik P. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. Eur. J. Pharmacol. 309:1996;159-165.
24. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
25. 2 receptors. Life Sci. 57:1995;57-62.
26. Mah S.J., Tang Y., Liauw P.E., Nagel J.E., Schneider A.S. Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release. Brain Res. 797:1998;173-180.
27. Maisonneuve I.M., Keller R.W. Jr, Glick S.D. Interactions between ibogaine, a potential anti-addictive agent, and morphine: An in vivo microdialysis study. Eur. J. Pharmacol. 199:1991;35-42.
28. Maisonneuve I.M., Keller R.W. Jr, Glick S.D. Interaction of ibogaine and d-amphetamine in rats: In vivo microdialysis and motor behavior in rats. Brain Res. 579:1992;87-92.
29. Mash D.C., Kovera C.A., Buck B.E., Norenberg M.D., Shapshak P., Hearn W.L., Samchez-Ramos J. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann. N. Y. Acad. Sci. 844:1998;274-292.
30. Mash D.C., Staley J.K., Baumann M.H., Rothman R.B., Hearn W.L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 57:1995;L45-PL50.
31. Mash D.C., Staley J.K., Pablo J.P., Holohean A.M., Hackman J.C., Davidoff R.A. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 192:1995;53-56.
32. Pearl S.M., Herrick-Davis K., Teitler M., Glick S.D. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine. Brain Res. 675:1995;342-344.
33. Popik P., Layer R.T., Fossom L.H., Benveniste M., Geter-Douslass B., Witkin J.M., Skolnick P. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J. Pharmacol. Exp. Ther. 275:1995;753-760.
34. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology. 114:1994;672-674.
35. Popik P., Layer R.T., Skolnick P. 100 years of ibogaine Neurochemical and pharmacological actions of a putative anti-addictive drug . Pharmacol. Rev. 47:1995;235-253.
36. Reid M.S., Hsu K. Jr, Souza K.H., Broderick P.A., Berger S.P. Neuropharmacological characterization of local ibogaine effects on dopamine release. J. Neural Transm. 103:1996;967-985.
37. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 237:1987;1219-1223.
38. Schoemaker H., Nickolson V.J. Dopamine uptake by rat striatal synaptosomes: Time- and temperature-dependent decay and protection by dithiothreitol and dopamine. J. Neurochem. 40:1983;922-928.
39. Sershen H., Hashim A., Harsing L., Lajtha A. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sci. 51:1992;1003-1011.
40. Sershen H., Hashim A., Lajtha A. Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats. Neurochem. Res. 19:1994;1463-1466.
41. 3-induced changes in stimulation-evoked dopamine release in vitro from striatum of C57BL/6By mice. Brain Res. Bull. 36:1995;587-591.
42. Sershen H., Hashim A., Lajtha A. Ibogaine and cocaine abuse Pharmacological interactions at dopamine and serotonin receptors . Brain Res. Bull. 42:1997;161-168.
43. Sheppard S.G. A preliminary investigation of ibogaine Case reports and recommendations for further study . J. Subst. Abuse Treat. 11:1994;379-385.
44. Staley J.K., Quyang Q., Pablo J., Hearn W.L., Flynn D.D., Rothman R.B., Rice K.C., Mash D.C. Pharmacological screen for activities of 12-hydroxyibogamine A primary metabolite of the indole alkaloid ibogaine . Psychopharmacology. 127:1996;10-18.
45. Sweetnam P.M., Lancaster J., Snowman A., Collins J.L., Perschke S., Bauer C., Ferkany J. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology. 118:1996;369-376.
46. Wei D., Maisonneuve I.M., Kuehne M.E., Glick S.D. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats. Brain Res. 800:1998;260-268.
47. Wheeler D.D., Edwards A.M., Chapman B.M., Ondo J.G. A model of the sodium dependence of dopamine uptake in rat striatal synaptosomes. Neurochem. Res. 18:1993;927-936.
48. Wise R.A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 19:1996;319-340.
49. 3H]imipramine II. Neuropharmacology. 26:1987;1081-1085.
50. Zetlet G., Singbartl G., Schlosser L. Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology. 7:1972;237-248.